Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study

BackgroundAmong patients with advanced non-small-cell lung cancer who were treated with nivolumab monotherapy, the association of peripheral blood count data (at baseline and 2 weeks after treatment initiation) with the early onset of immune-related adverse events (irAEs) and treatment efficacy has...

Full description

Bibliographic Details
Main Authors: Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura, Koichi Fukunaga, Masakazu Yamaguchi, Tomonori Nakamura
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
absolute lymphocyte count
biomarker
lymphocyte-to-monocyte ratio
neutrophil-to-lymphocyte ratio
nivolumab
non-small-cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.618570/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.618570/full

Similar Items